Luyan Pharma Co.,Ltd. (SHE:002788)
China
· Delayed Price · Currency is CNY 13.76
-0.40 (-2.82%)
Apr 29, 2026, 3:04 PM CST
Luyan Pharma Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 275.59 | 278.98 | 345.64 | 363.53 | 345.16 | 305.87 | Upgrade
|
| Depreciation & Amortization | 136.64 | 136.64 | 129.15 | 120.61 | 112.78 | 112.77 | Upgrade
|
| Other Amortization | 11.13 | 11.13 | 13.27 | 9.81 | 10.89 | 11.87 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.26 | -0.26 | -0.17 | -0.28 | -0.13 | 0.53 | Upgrade
|
| Asset Writedown & Restructuring Costs | 6.52 | 6.52 | 0.09 | 0.13 | 0.03 | 3.6 | Upgrade
|
| Loss (Gain) From Sale of Investments | 14.33 | 14.33 | 18.73 | 12.16 | 6.92 | -4.78 | Upgrade
|
| Provision & Write-off of Bad Debts | - | - | -3.53 | 12.95 | 32.39 | 23.61 | Upgrade
|
| Other Operating Activities | 27.19 | 192.44 | 215.91 | 228.19 | 244.96 | 201.89 | Upgrade
|
| Change in Accounts Receivable | -444.37 | -444.37 | -400.02 | 473.89 | -1,120 | -998.54 | Upgrade
|
| Change in Inventory | -176.36 | -176.36 | -292.39 | -29.27 | -276.23 | -253.58 | Upgrade
|
| Change in Accounts Payable | 672.29 | 672.29 | 560.47 | 129.3 | 886.8 | 232.66 | Upgrade
|
| Operating Cash Flow | 519.76 | 688.4 | 577.48 | 1,309 | 232.19 | -372.02 | Upgrade
|
| Operating Cash Flow Growth | -13.70% | 19.21% | -55.89% | 463.82% | - | - | Upgrade
|
| Capital Expenditures | -211.73 | -233.74 | -361.12 | -529.21 | -327.58 | -243.49 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.83 | 0.83 | 0.44 | 0.43 | 0.35 | 0.3 | Upgrade
|
| Cash Acquisitions | - | - | -0.15 | - | - | -1.86 | Upgrade
|
| Divestitures | - | - | - | 7.46 | - | -0.02 | Upgrade
|
| Investment in Securities | -8.38 | -10.09 | -8.9 | -12.92 | -2 | -31 | Upgrade
|
| Other Investing Activities | -0.58 | -0.58 | - | - | 0.08 | 0.92 | Upgrade
|
| Investing Cash Flow | -219.86 | -243.58 | -369.73 | -534.24 | -329.16 | -273.36 | Upgrade
|
| Long-Term Debt Issued | - | 9,500 | 8,943 | 8,945 | 8,680 | 6,654 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | - | -1.46 | Upgrade
|
| Long-Term Debt Repaid | - | -9,550 | -8,928 | -9,254 | -8,158 | -5,823 | Upgrade
|
| Total Debt Repaid | -9,904 | -9,550 | -8,928 | -9,254 | -8,158 | -5,824 | Upgrade
|
| Net Debt Issued (Repaid) | 146.99 | -49.27 | 14.55 | -308.61 | 522.09 | 830.02 | Upgrade
|
| Repurchase of Common Stock | - | - | - | - | - | -11.4 | Upgrade
|
| Common Dividends Paid | -312.33 | -313.96 | -323.83 | -340.1 | -331.07 | -250.08 | Upgrade
|
| Other Financing Activities | -79.35 | -76.86 | -19.28 | -60.27 | -6.55 | -92.85 | Upgrade
|
| Financing Cash Flow | -244.69 | -440.08 | -328.56 | -708.99 | 184.46 | 475.68 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.66 | -0.47 | 0.21 | 0.82 | 2.39 | -0.71 | Upgrade
|
| Net Cash Flow | 54.55 | 4.28 | -120.58 | 66.71 | 89.87 | -170.4 | Upgrade
|
| Free Cash Flow | 308.03 | 454.66 | 216.36 | 779.91 | -95.4 | -615.51 | Upgrade
|
| Free Cash Flow Growth | 3.46% | 110.14% | -72.26% | - | - | - | Upgrade
|
| Free Cash Flow Margin | 1.44% | 2.14% | 1.06% | 3.93% | -0.49% | -3.51% | Upgrade
|
| Free Cash Flow Per Share | 0.79 | 1.17 | 0.56 | 2.02 | -0.25 | -1.59 | Upgrade
|
| Cash Income Tax Paid | 405.45 | 397.36 | 384.88 | 377.42 | 353.85 | 342.77 | Upgrade
|
| Levered Free Cash Flow | - | - | 67.86 | 409.7 | -195.36 | -889.06 | Upgrade
|
| Unlevered Free Cash Flow | - | - | 197.04 | 548.98 | -58.42 | -770.14 | Upgrade
|
| Change in Working Capital | 48.63 | 48.63 | -141.6 | 562 | -520.81 | -1,027 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.